Sign in or create an account to add this stock to your watchlist.
About Proteon Therapeutics (NASDAQ:PRTO)
Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRTO
CUSIPN/A
Phone781-890-0102
Debt
Debt-to-Equity RatioN/A
Current Ratio4.22
Quick Ratio4.22
Price-To-Earnings
Trailing P/E Ratio-0.96
Forward P/E Ratio-1.39
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.45 per share
Price / Book4.56
Profitability
EPS (Most Recent Fiscal Year)($2.13)
Net Income$-29,960,000.00
Net MarginsN/A
Return on Equity-172.29%
Return on Assets-71.78%
Miscellaneous
Employees16
Outstanding Shares17,670,000
Proteon Therapeutics (NASDAQ:PRTO) Frequently Asked Questions
What is Proteon Therapeutics' stock symbol?
Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO."
How were Proteon Therapeutics' earnings last quarter?
Proteon Therapeutics (NASDAQ:PRTO) released its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.37) by $0.03. View Proteon Therapeutics' Earnings History.
When is Proteon Therapeutics' next earnings date?
What price target have analysts set for PRTO?
4 analysts have issued 1 year target prices for Proteon Therapeutics' stock. Their forecasts range from $3.00 to $3.00. On average, they anticipate Proteon Therapeutics' stock price to reach $3.00 in the next twelve months. View Analyst Ratings for Proteon Therapeutics.
Who are some of Proteon Therapeutics' key competitors?
Some companies that are related to Proteon Therapeutics include Pluristem Therapeutics (PSTI), Aptose Biosciences (APTO), Krystal Biotech (KRYS), Applied Genetic Technologies (AGTC), Aevi Genomic Medicine (GNMX), Cidara Therapeutics (CDTX), Curis (CRIS), Brainstorm Cell Therapeutics (BCLI), Genocea Biosciences (GNCA), BioCardia (BCDA), Champions Oncology (CSBR), BiondVax (BVXV), TRACON Pharmaceuticals (TCON), CytRx (CYTR) and Microbot Medical (MBOT).
Who are Proteon Therapeutics' key executives?
Proteon Therapeutics' management team includes the folowing people:
- Mr. Timothy P. Noyes, CEO, Pres & Director (Age 56)
- Mr. George A. Eldridge, Sr. VP, CFO, Treasurer & Assistant Sec. (Age 55)
- Dr. Steven Keith Burke M.D., Sr. VP & Chief Medical Officer (Age 57)
- Mr. Matthew P. Kowalsky, VP of Legal & Sec. (Age 45)
- Mr. Daniel P. Gottlieb, VP of Corp. Devel. (Age 48)
Has Proteon Therapeutics been receiving favorable news coverage?
News articles about PRTO stock have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Proteon Therapeutics earned a news sentiment score of 0.21 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 45.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Proteon Therapeutics?
Shares of PRTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Proteon Therapeutics' stock price today?
One share of PRTO stock can currently be purchased for approximately $2.05.
How big of a company is Proteon Therapeutics?
Proteon Therapeutics has a market capitalization of $38 million. The biopharmaceutical company earns $-29,960,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Proteon Therapeutics employs 16 workers across the globe.
How can I contact Proteon Therapeutics?
Proteon Therapeutics' mailing address is 200 WEST STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 781-890-0102 or via email at [email protected]
MarketBeat Community Rating for Proteon Therapeutics (PRTO)
MarketBeat's community ratings are surveys of what our community members think about Proteon Therapeutics and other stocks. Vote "Outperform" if you believe PRTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTO will underperform the S&P 500 over the long term. You may vote once every thirty days.
Proteon Therapeutics (NASDAQ:PRTO) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Proteon Therapeutics in the last 12 months. Their average twelve-month price target is $3.00, suggesting that the stock has a possible upside of 46.34%. The high price target for PRTO is $3.00 and the low price target for PRTO is $3.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Hold | Hold | Hold |
| Consensus Rating Score: | 2.50 | 2.40 | 2.20 | 2.11 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
8 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $3.00 | $3.6667 | $3.4333 | $6.86 |
| Price Target Upside: | 46.34% upside | 70.54% upside | 85.59% upside | 270.81% upside |
Proteon Therapeutics (NASDAQ:PRTO) Consensus Price Target History
Proteon Therapeutics (NASDAQ:PRTO) Analyst Ratings History
Show:
(Data available from 5/24/2016 forward)
Proteon Therapeutics (NASDAQ:PRTO) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Proteon Therapeutics (NASDAQ PRTO) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 45.70%
Institutional Ownership Percentage: 50.60%
Proteon Therapeutics (NASDAQ PRTO) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/15/2017 | Steven Keith Burke | SVP | Buy | 12,000 | $1.88 | $22,560.00 | 117,535 |  |
| 11/30/2017 | James E Flynn | Director | Buy | 110,557 | $1.75 | $193,474.75 | | |
| 11/14/2017 | George Arthur Eldridge | CFO | Buy | 295 | $1.69 | $498.55 | | |
| 6/6/2016 | George Arthur Eldridge | CFO | Buy | 4,000 | $5.78 | $23,120.00 | 2,750 | |
| 12/1/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $14.97 | $74,850.00 | | |
| 11/2/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $13.50 | $67,500.00 | | |
| 10/1/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $13.33 | $66,650.00 | | |
| 9/8/2015 | Timothy P. Noyes | CEO | Sell | 5,000 | $13.55 | $67,750.00 | | |
| 7/7/2015 | Daniel Philip Gottlieb | VP | Sell | 1,965 | $16.86 | $33,129.90 | | |
| 10/27/2014 | James E Flynn | Insider | Buy | 691,713 | $10.00 | $6,917,130.00 | | |
| 10/27/2014 | Skyline Venture Partners Quali | Major Shareholder | Sell | 56,038 | $10.00 | $560,380.00 | | |
| 10/27/2014 | Timothy Haines | Director | Buy | 950,000 | $10.00 | $9,500,000.00 | | |
(Data available from 1/1/2013 forward)
Proteon Therapeutics (NASDAQ PRTO) News Headlines
| Source: |
|
Proteon Therapeutics (NASDAQ:PRTO) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Proteon Therapeutics (NASDAQ:PRTO) Income Statement, Balance Sheet and Cash Flow Statement
Proteon Therapeutics (NASDAQ PRTO) Stock Chart for Thursday, May, 24, 2018
Loading chart…
